Serious adverse events by system organ class and treatment arm by study day 29.
pneumonia, pulmonal hypertension, tracheitis, bacteremia, covid deterioration, Streptococcus mitis bacteremia, nosocomial infection
PNEUMONIA, LUNG FIBROSIS, TRACHEITIS, PNEUMOTHORAX, HYPERTENSION, RESPIRATORY FAILURE, PNEUMOMEDIASTINUM, BACTERIAL PNEUMONIA, PULMONARY EMBOLUS, NOSOCOMIAL INFECTION, STAPHYLOCOCCUS AUREUS SEPTICAEMIA, ASPIRATION PNEUMONIA
Number of patients with any SAE: 13 in UC group, 14 in Anakinra group and 6 in Tocilizumab group. Some patients had more than one SAE.^Infections: UC group: 1 Staphylococcus aureus septicaemia and 1 ventilator–associated pneumonia (same patient), 1 bacterial pneumonia, 1 post intubation tracheitis. In the anakinra group: 1 Streptococcus mitis bacteremia and 1 E Coli bacteremia (same patient), 1 Post–covid deterioration. In the tocilizumab group: 1 nosocomial infection of unknown origin.*10 in the UC group had respiratory failure/progress of respiratory failure. 3 pulmonary emboli, 1 pneumothorax, 1 aspiration pneumonia. 1 pulmonal hypertension. In the anakinra group: 13 had respiratory failure/progress of respiratory failure, 1 pulmonary embolus, 1 pneumothorax. In the tocilizumab group: 7 had respiratory failure/progress of respiratory failure, 1 pneumomediastinum, 1 lung fibrosis, 1 pulmonal hypertension